STEVANATO GROUP S.P.A.
Stevanato Group S.p.A. (STVN) is an Italian-based supplier of primary packaging and drug containment solutions for the pharmaceutical and biotechnology industries. The company produces glass vials, syringes, cartridges and other sterile containment systems, and offers assembly and inspection services to customers developing vaccines, biologics and injectable medicines. With a market capitalisation of about $7.19 billion, Stevanato’s performance is linked to global pharmaceutical demand, adoption of advanced delivery formats and regulatory standards for sterile packaging. The business is capital-intensive and benefits from long-term customer contracts, but faces risks such as raw material costs, currency fluctuations and customer concentration. Investors should weigh growth prospects from biologics and onshoring trends against cyclical healthcare spending and execution risks. This content is educational only and not personal advice; values can fall as well as rise, and past performance is not a reliable indicator of future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Stevanato Group's stock with a target price of $29, indicating good potential for growth.
Financial Health
Stevanato Group is performing well with solid revenue and profit margins, indicating strong market demand.
Dividend
Stevanato Group's dividend yield of 0.35% is low, indicating limited income potential for investors. If you invested $1000, you would be paid $3.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring STVN
Pharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Strong demand drivers
Rising biologics and injectable therapies support long-term demand, though growth depends on customer contracts and industry cycles.
Global manufacturing reach
A footprint across regions helps serve multinational pharma firms, but also exposes the company to currency and supply-chain risks.
Innovation and risks
Investments in advanced containment and inspection can create competitive edge; however, the business is capital-intensive and execution matters.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
